Lonza, BioWa Form Licensing Agreement with arGEN-X BVBy
BioWa Inc. and Lonza have entered into a licensing agreement with arGEN-X BV, a clinical-stage human therapeutic antibody company. arGEN-X has licensed the companies' POTELLIGENTÂ® CHOK1SV Cell Line Technology for use in the development of ARGX-110, a proprietary antibody in its pipeline.
POTELLIGENTÂ® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the BioWa's engineered glycosylation POTELLIGENTÂ® technology with Lonza's GS Gene Expression Systemâ„¢. The GS Systemâ„¢ includes Lonza's pre-eminent host cell line, CHOK1SV. POTELLIGENTÂ® technology is designed to improve the potency and efficacy of therapeutic antibodies by enhancing antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.
This agreement follows a licensing agreement between arGEN-X and BioWa, initiated in 2010, to apply BioWa's POTELLIGENTÂ® Technology to therapeutic antibodies discovered by arGEN-X.
ARGX-110 is a monoclonal antibody targeting CD70 positive tumors with three distinct modes of action: potent tumor cell depletion through enhanced ADCC and deprivation of both a key stimulation signal and immune privilege.